Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dimenhydrinate
Drug ID BADD_D00676
Description Dimehydrinate was first described in the literature in 1949,[A233120] and patented in 1950.[L32995] Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.[A233130] Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.[L32980,L32985,L32995] Dimenhydrinate is a combination of [Diphenhydramine] and [8-chlorotheophylline] in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline.[L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.[A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.[A1539] Dimenhydrinate was granted FDA approval on 31 May 1972.[L32975]
Indications and Usage Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.[L32980,L32985]
Marketing Status approved
ATC Code R06AA11
DrugBank ID DB00985
KEGG ID D00520
MeSH ID D004111
PubChem ID 10660
TTD Drug ID D0U8UV
NDC Product Code 10237-940; 63323-366; 70677-0022; 0904-6772; 29485-1216; 29485-6925; 63029-901; 63868-034; 12711-4675; 10237-941; 11673-198; 46122-536; 52904-962; 63029-910; 0363-1980; 10267-1006; 63029-902; 49873-802; 50844-199; 63941-198; 67751-170; 10267-4186; 49452-2615; 55745-0002; 11822-0198; 36800-930; 0363-0198; 66715-9809; 70000-0404; 70677-1087; 62011-0341; 67091-118; 0904-2051; 10267-4215; 10237-942; 49035-981; 69842-206; 29485-8048; 50804-198
UNII JB937PER5C
Synonyms Dimenhydrinate | Diphenhydramine Theoclate | Theoclate, Diphenhydramine | Wehamine | Aviomarin | Biodramina | Calm-X | Calm X | Cinfamar | Contramareo | Dimen Heumann | Heumann, Dimen | Dimen Lichtenstein | Lichtenstein, Dimen | Dimetabs | Dinate | DMH | Dramanate | Gravol | Marmine | Motion-Aid | Motion Aid | Nausicalm | Reisegold | Reisetabletten Lünopharm | Lünopharm, Reisetabletten | Reisetabletten Stada | Stada, Reisetabletten | Reisetabletten-ratiopharm | Reisetabletten ratiopharm | Rodovan | RubieMen | Superpep | Travel Well | TripTone | Vertigo-Vomex | Vertigo Vomex | Vomex A | Vomacur | Vomisin | Dramamine | Apo-Dimenhydrinate | Apo Dimenhydrinate
Chemical Information
Molecular Formula C17H21NO.C7H7ClN4O2
CAS Registry Number 523-87-5
SMILES CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005---
Thrombosis24.01.01.006---
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
General physical health deterioration08.01.03.018---
Balance disorder08.01.03.081; 17.02.02.007---
Epigastric discomfort07.01.02.004---
Skin burning sensation17.02.06.009; 23.03.03.021---
Hypoaesthesia oral07.05.05.003; 17.02.06.021---
Drug resistance08.06.01.005---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Feeding disorder14.03.02.003; 19.09.01.003---
Decreased appetite08.01.09.028; 14.03.01.005--
Increased bronchial secretion22.12.01.002---
Hypophagia07.01.06.010; 14.03.01.006; 19.09.01.004---
The 4th Page    First    Pre   4    Total 4 Pages